Efficacy and safety of colchicine for pericarditis prevention : systematic review and meta-analysis by M. Imazio et al.
ORIGINAL ARTICLE
Efficacy and safety of colchicine for pericarditis
prevention. Systematic review and meta-analysis
Massimo Imazio,1 Antonio Brucato,2,3 Davide Forno,1 Silvia Ferro,1 Riccardo Belli,1
Rita Trinchero,1 Yehuda Adler4
ABSTRACT
Objectives The purpose of this study was to investigate
the efficacy and safety of colchicine for pericarditis
prevention.
Background Recurrent pericarditis prevention is a major
management goal that may reduce morbidity and
management costs. Although empiric anti-inflammatory
therapy is considered the mainstay of treatment, no
specific drug has been proven to be efficacious for
prevention but colchicine.
Methods Controlled clinical studies were searched in
several databases and were included provided they
focused on the pharmacologic primary or secondary
prevention of pericarditis. We performed a meta-analysis
including studies primary outcome, adverse events, and
drug withdrawal.
Results From the initial sample of 127 citations, five
controlled clinical trials were finally included (795
patients): three studies were double-blind randomised
controlled trials, and two studies were open-label
randomised controlled trials. Trials followed patients for
a mean of 13 months. Meta-analytic pooling showed
that colchicine use was associated with a reduced risk of
pericarditis during follow-up (RR¼0.40, 95% CI 0.30 to
0.54, p for effect <0.001, p for heterogeneity ¼ 0.95,
I2¼0%) either for primary or secondary prevention
without a significant higher risk of adverse events
compared with placebo (RR¼1.22, 95% CI 0.71 to
2.10, p for effect 0.48, p for heterogeneity ¼ 0.44,
I2¼0%), but more cases of drug withdrawals (RR¼1.85,
95% CI 1.04 to 3.29, p for effect 0.04, p for
heterogeneity ¼ 0.42, I2¼0%). Gastrointestinal
intolerance is the most frequent side effect (mean
incidence 8%), but no severe adverse events were
recorded.
Conclusions Available evidence suggests that
colchicine is safe and efficacious for the primary and
secondary prevention of pericarditis.
Optimal medical management of pericarditis is
a relatively common clinical problem; especially
prevention of recurrences is a difﬁcult issue.
Recurrent pericarditis has been reported in 25% to
50% of cases,1 2 often the most troublesome and
common complication of pericarditis.3 Recurrences
are often a cause of re-hospitalisation and repetition
of diagnostic tests. On this basis, prevention of
pericarditis is a treatment goal that may improve
the quality of life of patients and reduce disease
management costs.
Unfortunately, the pathogenesis of recurrences is
not well known, although recent published
evidence of serum anti-heart (AHA) and anti-inter-
calated-disk (AIDA) in patients with idiopathic
recurrent pericarditis, strengthens the autoimmune
etiopathogenesis of these forms, often suspected to
have an immune-mediated origin.4 Thus, in clinical
practice, using a conventional diagnostic approach,
most cases of acute or recurrent pericarditis
are labelled as ‘idiopathic’. Idiopathic, viral, post-
operative pericarditis in the setting of the post-
pericardiotomy syndrome after cardiac surgery, as
well as uncomplicated pericarditis related to
a systemic inﬂammatory disease5 have similar
empiric anti-inﬂammatory therapies, that are
considered the mainstay of treatment for pericar-
ditis.3 No speciﬁc drug has been proven to be efﬁ-
cacious for prevention beyond treatment, with the
possible important exception of colchicine.6 7
On this basis, we aimed to summarise the
available data on pharmacologic primary and
secondary prevention of pericarditis by colchicine
and determine its efﬁcacy and safety in available
clinical trials. To the best of our knowledge this is
the ﬁrst systematic review on this issue.
METHODS
Selection criteria and search strategy
We included any randomised clinical trial on phar-
macological prevention of pericarditis. Potentially
relevant studies published up to December 2011
were searched in BioMedCentral, the Cochrane
Collaboration Database of Randomised Trials
(CENTRAL), ClinicalTrials.gov, EMBASE, Google
Scholar, MEDLINE/PubMed, and Scopus. The
PubMed search was performed with the term
‘pericarditis’ and ‘colchicine’. Recent (2005 or later)
conference proceedings from the American Heart
Association, American College of Cardiology, and
the European Society of Cardiology were electron-
ically or manually searched. Searches were not
limited by language, sex, or age. In addition,
references of retrieved studies were scanned for
additional unpublished studies.
Study selection and data collection
Initially retrieved references were checked at the
title/abstract level for pertinence. Potentially perti-
nent studies were retrieved as full reports for further
appraisal according to the following selection
criteria. Inclusion criteria to be fulﬁlled for data
extraction were: (1) controlled clinical trial, (2)
head-to head comparisons of treatments or versus
placebo, (3) for the primary or secondary prevention
of pericarditis. Final study selection for inclusion in
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the review was performed by two independent reviewers (DF
and SF), with divergences resolved by consensus.
Study evaluation included general methodological quality
features, including sequence-generation, blinding, use of
intention-to-treat analysis, completeness of follow-up, and
allocation concealment.8 9
Baseline, outcome, and adverse events data were retrieved
from included studies, focusing on the pharmacologic treatment
(dose, timing, and duration of administration), primary and
secondary clinical end points, and adverse events. We extracted
data on the incidence of pericarditis and recurrences. We also
extracted data on adverse events including gastrointestinal
intolerance, increases in ASTand ALT, CK, myotoxicity, alopecia,
or any possible side effect related to colchicine. Data on drug
withdrawal were recorded and included in the meta-analysis.
Data abstraction and validity/risk of bias appraisal were
performed on pre-speciﬁed electronic forms by two independent
reviewers (DF and SF), with divergences resolved by consensus.
Data analysis
In order to assess inter-rater reliability on inclusion of articles,
we calculated the f statistic, which provides a measure of inter-
observer agreement independent of chance.
Categorical variables are reported as percentages. Statistical
homogeneity and consistency were checked by means of c2 test
and I2. I2 is computed as 100%3 (Qdf)/Q, where Q is Cochran
heterogeneity statistic and df the degrees of freedom. A value of
0% indicates no observed heterogeneity, and larger values
show increasing heterogeneity. We calculated the RR and
appropriate 95% CI of outcomes, adverse events, and drug
withdrawal according to the number of events reported in the
original studies on an intention-to-treat basis. Computations
were carried out with RevMan V.5.0 (The Nordic Cochrane
Centre, Copenhagen, Denmark) and the software package SPSS
V.13.0.
RESULTS
Figure 1 displays the ﬂow diagram of study inclusion. From
initial sample of 127 citations, 14 citations were appraised in
complete form for more detailed evaluation, leading to the ﬁnal
inclusion of ﬁve controlled clinical trials (treatment comparison
was colchicine vs placebo) for the prevention of pericarditis
(table 1).1 2 10e12 Included studies enrolled a total of 795
patients. The inter-rater reliability for study inclusion was very
good (f>0.9).
Baseline features of the selected studies are reported in table 2:
two studies were aimed at the primary prevention of post-
operative pericarditis,10 11 and the other three for the secondary
prevention of pericarditis.1 2 12 Study quality was relatively high
with a low overall risk of bias (ﬁgure 2). All studies reported on
who was blinded in the trial, and provided follow-up data,
adequate methods of randomisation sequence generation,
concealed allocation of study participants, and intention-to-treat
analysis in 4 of 5 (80%).1 2 11 12
Pericarditis prevention
Trials followed patients for a mean of 13 months. Meta-analytic
pooling showed that colchicine use was associated with
a reduced risk of pericarditis during follow-up (RR¼0.40, 95% CI
0.30 to 0.54, p for effect <0.001, p for heterogeneity ¼ 0.95,
I2¼0%) either for primary (RR¼0.44, 95% CI 0.27 to 0.70, p for
effect <0.001, p for heterogeneity ¼ 0.80, I2¼0%) or secondary
prevention (RR¼0.39, 95% CI 0.27 to 0.56, p for effect <0.001, p
for heterogeneity ¼ 0.77, I2¼0%). Colchicine was efﬁcacious
either for the primary or secondary prevention of pericarditis
(ﬁgure 3). Inspection of the funnel plot did not suggest the
presence of publication bias.
Adverse events and drug withdrawal
One clinical trial was excluded from analysis because 52 of 163
patients (31.9%) were excluded from subsequent outcome
assessment for side effects or other complications.10 Meta-
analytic pooling showed that colchicine use was not associated
with an increased risk of side effects compared with placebo
(RR¼1.22, 95% CI 0.71 to 2.10, p for effect 0.48, p for hetero-
geneity ¼ 0.44, I2¼0%) (ﬁgure 4). The most common reported
side effect was gastrointestinal intolerance that was associated
Figure 1 Flow diagram of included studies.
Table 1 Mean features of included studies
Study Location/year Design Setting Therapeutic class Patients Number* Follow-up (months)
Finkelstein Y et al10 Israel/2002 Double-blind RCT Multicenter Colchicine 111 3
COPE study1 Italy/2005 Open-label RCT Single center Colchicine 120 18
CORE study2 Italy/2005 Open-label RCT Single center Colchicine 84 18
COPPS study11 Italy/2010 Double-blind RCT Multicenter Colchicine 360 12
CORP study12 Italy/2011 Double-blind RCT Multicenter Colchicine 120 18
*Real study population included for results analysis in the original study.
RCT, randomised clinical trial.
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with drug withdrawal in almost all cases. Colchicine use is
associated with an increased risk of drug withdrawal (RR¼1.85,
95% CI 1.04 to 3.29, p for effect 0.04, p for heterogeneity ¼ 0.42,
I2¼0%) (ﬁgure 5). A severe adverse event was considered an
untoward event which was fatal or life-threatening or required
hospitalisation or was signiﬁcantly or permanently disabling or
medically signiﬁcant (may jeopardise the patient and may
require medical or surgical intervention to prevent an adverse
outcome). No severe side effects were reported in clinical trials.
A detailed list of all reported side effects together with colchicine
doses and study exclusion criteria is reported in table 3.
DISCUSSION
Recurrent pericarditis is the most troublesome complication of
pericarditis. Although different anti-inﬂammatory agents are
used for treatment (ie, acetylsalicylic acid, indomethacin,
steroids, and colchicine), only colchicine has been proven to be
efﬁcacious for prevention. In the present systematic review,
multiple databases were searched without language restrictions
leading to the selection of ﬁve controlled clinical studies on
colchicine use for the prevention of pericarditis. Colchicine was
safe and efﬁcacious in all randomised clinical trials on adult
patients for the primary and secondary prevention of pericarditis
(RR¼0.40, 95% CI 0.30 to 0.54; p<0.001) without a signiﬁcant
increase of side effects compared to placebo (RR¼1.22, 95% CI
0.71 to 2.10, p¼0.48), but a higher risk of drug withdrawal
(RR¼1.85, 95% CI 1.04 to 3.29), p¼0.04). Colchicine concen-
trates in white blood cells, particularly neutrophils, inhibiting
tubulin polymerisation, thus interfering with migration and
Table 2 Baseline features of patients in included studies
Study
Mean
age (years) Male (%) Intervention
Finkelstein Y
et al10
64 81/111 (73.0) Colchicine 1.5 mg/day
(in three doses) from 3rd
postoperative day for 1 month
COPE study1 57 54/120 (45.0) Colchicine 1.0e2.0 mg for
the first day followed by a
maintenance dose of
0.5e1.0 mg daily for 3 months*
CORE study2 51 29/84 (34.5) Colchicine 1.0e2.0 mg for
the first day followed by a
maintenance dose of
0.5e1.0 mg daily for 6 months*
COPPS study11 66 239/360 (66.4) Colchicine 1.0e2.0 mg for the
first day followed by a
maintenance dose of
0.5e1.0 mg daily for 1 month*
CORP study12 48 63/120 (52.5) Colchicine 1.0e2.0 mg for
the first day followed by a
maintenance dose of
0.5e1.0 mg daily for 6 months*
*Highest dose in patients $70 kg, and the lowest dose for patients <70 kg or intolerant to
the highest dose. Colchicine was given as adjunct to aspirin or NSAID in acute and recurrent
pericarditis (COPE, CORE, and CORP studies).
Figure 2 Risk of bias summary: review authors’ judgements about
each risk of bias item for each included study. Empty boxes indicate
unclear risk of bias. The green circle indicates a low risk of bias, the red
circle identifies potential risk of bias (in the figure specifically related to
the open-label randomised trial design of the COPE and CORE studies).
Figure 3 Forest plot for the risk of
pericarditis. M-H, Mantel-Haenszel.
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phagocytosis, and reducing the inﬂammatory cycle.3 6 7
Although the exact number of responders is unknown, the
drug has been successfully used for the treatment and preven-
tion of recurrences and to taper corticosteroids in patients
with combined therapies including steroids with non-steroidal
anti-inﬂammatory drugs.7 However, a careful monitoring of
possible contraindications, drug interactions and side effects
is necessary.5 13 14 Colchicine shows a large interindividual
bioavailability. Furthermore, interactions with drugs interfering
with CYP3A4 dependent enzymes and P-glycoprotein occur and
are clinically important. The drug has a narrow therapeutic-
toxicity window, and potentially serious drug-drug interactions
(eg, with clarithromycin and cyclosporine) are better recognised
and therefore preventable. The dosage of colchicine must be
reduced in patients with relevant hepatic and/or renal
dysfunction, and the elderly. However, when appropriately used
and contraindications have been excluded, oral colchicine at
0.5e1.0 mg has been shown to be a safe treatment.1 2 10e12
However safe use of the drug requires careful consideration of
potential contraindications. Colchicine is indicated for patients
without bacterial or neoplastic pericarditis and patients were
excluded from clinical trials in case of known severe liver disease
or current transaminases >1.5 times the upper normal limit,
current serum creatinine above 2.5 mg/dl, known myopathy or
current serum creatine kinase above the upper normal limit,
known blood dyscrasias or gastrointestinal disease, pregnant and
lactating women or women of childbearing potential not
protected by a contraception method, known hypersensitivity
to colchicine.1 2 11 12
Use of weight adjusted doses (0.5 mg as maximum dose for
patients <70 kg) and avoidance of attack doses $1.0 mg daily
may be useful to reduce gastrointestinal intolerance.5 A higher
rate of gastrointestinal side effects has been reported with daily
doses >1.0 mg in the study by Finkelstein Y et al (table 3).
Previous reviews on the topic have suggested the safety and
efﬁcacy of the drug for pericarditis treatment based on expert
opinion and previous retrospective or non-randomised observa-
tions. A previous meta-analysis on medical treatments for peri-
carditis has demonstrated that colchicine use was associated
with a reduced risk of treatment failure (OR¼0.23, 95% CI 0.11
to 0.49) and recurrent pericarditis (OR¼0.39, 95% CI 0.20 to
0.77), but with a trend towards more adverse effects (OR¼5.27,
95% CI 0.86 to 32.16).15 However this meta-analysis did not
include recently published clinical trials.11 12 In another meta-
analysis focused on the prevention of the post-pericardiotomy
syndrome, colchicine use was associated a decreased risk of the
syndrome (OR¼0.38, 95% CI 0.22 to 0.65).16 However this
meta-analysis did not include clinical trials for secondary
prevention of pericarditis not related to the post-pericardiotomy
syndrome.
The present meta-analysis focused on prevention of pericar-
ditis by colchicine, includes all published clinical trials
and extends current knowledge showing either efﬁcacy or safety
of the drug when used at low doses and with appropriate indi-
cations and contraindications. However colchicine use is
associated with more cases of drug withdrawal because of
gastrointestinal intolerance. On this basis, the present meta-
analysis provides a stronger evidence base for the use of colchi-
cine in patients with pericarditis, as outlined in previous
recommendations on colchicine use in the 2004 guidelines on the
management of pericardial diseases of the European Society of
Cardiology, based on expert consensus while randomised trials
were not available at that time.17 At present, there are no
available updates of 2004 guidelines, and no speciﬁc guidelines
on the management of pericardial diseases have been issued by
the American College of Cardiology, and the American Heart
Association. This meta-analysis is useful to summarise data
from all published clinical trials on pericarditis prevention by
colchicine.
In conclusion, our study found that colchicine 0.5e1.0 mg
daily was safe and efﬁcacious for the primary and secondary
prevention of pericarditis and should be considered as ﬁrst line
therapy for pericarditis prevention.
Study strengths
At present, this is the ﬁrst comprehensive meta-analysis on this
topic, including all published clinical trial up to December 2011.
We believe that a rigorous search strategy has resulted in
a comprehensive systematic review and meta-analysis on the
efﬁcacy and safety of colchicine for pericarditis prevention.
Study quality was relatively high with a low overall risk of bias
and the level of heterogeneity was negligible.
Figure 4 Forest plot for the risk of
adverse events.
Figure 5 Forest plot for the risk of
drug withdrawal.
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Study limitations
Some of the included trials were open label, which might have
introduced bias; however our ﬁndings were similar in open-label
and placebo-controlled trials. However all trials have indepen-
dent blinded outcome assessment with very low or absent
participant dropout, thus indicating studies of high quality.
Although an apparently heterogeneous population (idiopathic,
viral, postoperative pericarditis as well as pericarditis related to
a systemic inﬂammatory disease) has been included in the
present systematic review, the same treatment and preventive
strategies are adopted and recommended for such patients, that
are heterogeneous for aetiology but homogenous for pericarditis
medical therapy. Only bacterial and neoplastic pericarditis has
been excluded because requiring speciﬁc treatments. The last
potential limitation of the present study is the inclusion of trials
exploring primary and secondary prevention of pericarditis.
However the aim of the meta-analysis was to provide
a comprehensive review of efﬁcacy and safety of colchicine for
both primary and secondary prevention, thus comparing and
summarising both the effects. We think that this updated review
may be useful in the clinical setting and provides a stronger
evidence base for future recommendations and clinical research
in the ﬁeld.
CONCLUSIONS
At present colchicine is the only drug that has been proven
efﬁcacious and safe for pericarditis prevention in clinical trials,
with a similar effect for primary and secondary prevention. On
this basis, the drug should be considered as a ﬁrst line agent for
pericarditis prevention.
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Table 3 Adverse events reported in clinical trials
Finkelstein
et al10
COPE
study1
CORE
study2
COPPS
study11
CORP
study12
Gastrointestinal NA* 6.7 vs 8.3 14.0 vs 7.0 4.4 vs 8.9 5.0 vs 7.0
Alopecia NA 0 vs 0 0 vs 0 0 vs 0 0 vs 0
Anorexia NA 0 vs 0 0 vs 0 0 vs 0 0 vs 0
Hepatotoxicity NA 0 vs 0 0 vs 0 0 vs 0 2.0 vs 0
Myotoxicity NA 0 vs 0 0 vs 0 1 vs 0 0 vs 0
Bone marrow
toxicity
NA 0 vs 0 0 vs 0 0 vs 0 0 vs 0
Drug withdrawal NA 0.0 vs 8.3 0.0 vs 7.0 6.7 vs 11.7 7.0 vs 8.0%
Data are reported as percentages with comparison placebo versus colchicine. For all
comparison p values>0.05.
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NA, not available.
PAGE fraction trail=4.75
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